In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Individuals will obtain treatment until finally ailment progression or maybe the participants are unable to tolerate the study drugs. All round, our present-day work highlights the potential utilization of ARV-825 in https://sparkye333qbl5.frewwebs.com/profile